Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
Shionogi President and CEO Isao Teshirogi said on January 30 that the company expects what it calls the “QOL disease” business to gain momentum following the addition of research staff from Japan Tobacco’s (JT) former pharmaceutical division. The Osaka drug…
To read the full story
Related Article
- Shionogi to Absorb Torii in April 2027
February 24, 2026
- Shionogi Completes Takeover of JT’s Pharma Business
December 2, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Shionogi Completes Full Takeover of Torii under JT Deal
September 2, 2025
- Shionogi, Torii to Start Co-Promotion in September upon Takeover
July 29, 2025
- Shionogi Clinches Tender Offer for Torii, Sets Stage for Full Takeover by September
June 20, 2025
- Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz
May 8, 2025
- Shionogi Set to Make “QOL Diseases” Next Leg of Business: CEO
October 29, 2024
BUSINESS
- Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
- Expert Highlights Subcutaneous Benefits of Rybrofaz in Lung Cancer
April 6, 2026
- NEC Bio, Transgene Strike Licensing Deal for Cancer Vaccine
April 6, 2026
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…